Zhangjiang Pilot Biopharmaceutical Contract Production To Assist Biopharmaceutical Innovation Strategy

　　Original title: Zhang Jiang is expected to pilot the biopharmaceutical contract production as a key initiative in Shanghai to promote the biopharmaceutical contract production (CMO), Zhangjiang biopharmaceutical base in conjunction with German pharmaceutical giant Bo
Linging Ingerheim tailor-made biopharmaceutical manufacturing building recently announced the completion of construction, will introduce professional equipment, technology, technology and standards in line with international standards, to promote a large number of innovation spree.　　In accordance with the current domestic regulations, drug listing license and production license to adopt a "bundled" management model - drug approval number is only issued to the "drug production license" of the production enterprises This means that domestic pharmaceutical enterprises must build their own plant, in order to complete the production stage of new drugs, huge input costs will make a large number of small and medium-sized innovation subjects look forward to sighing Now this policy restrictions are about to break through, reporters learned that CMO contract production is expected to soon land in Zhangjiang.　　In order to help small and medium-sized pharmaceutical enterprises "accelerate" the development of new drugs, Zhang Jiang found a large number of global biopharmaceutical contract manufacturing experience
of Bollinger Ingeheim, to build the first domestic centralized biopharmaceutical base with international standards As an important part of the base, the recently handed-over manufacturing building was tailored by Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd in accordance with the international standards of Bollinger Ingeheim Biopharmaceuticals Through the base, Bollinger Ingerheim is expected to be the first to pilot biopharmaceutical contract production, providing biopharmaceutical companies large and small with a full range of services from production process development, clinical research samples to commercial supply.　　In June, Bollinger Ingeheim and the Pudong New Area Government signed a Memorandum of Understanding on promoting the biopharmaceutical manufacturing industry, and the company plans to invest more than 100 million euros over the next five years in the construction and operation of china's biopharmaceutical base At present, the pilot workshop of the base for the production of toxicology samples and early clinical supply has been put into operation, and the commercial supply is expected to be put into production in the first quarter of 2017.　　"We hope to further accelerate the construction of biopharmaceutical bases and launch a pilot biopharmaceutical contract production pilot with the support of relevant government departments, turning the 'production bottlenecks' in the original biopharmaceutical industry chain into 'service platforms'," said Luo Jiali, general manager of Bollinger Ingham Biopharmaceuticals (China) Co., Ltd Drug research and development enterprises only need to focus on the development of innovative drugs themselves, and drug manufacturers will focus on commercial production processes and quality control, thereby helping research and development enterprises in the development of new drugs to achieve industrialization "